+44 (0)1223 330484
enquiries@hughes.cam.ac.uk

Changing lives: Hughes By-Fellow to open new cancer lab in Italy

Dr Perla Pucci has been awarded international funding to launch a new cancer research group.

Dr Pucci will establish the new laboratory in Italy advancing work to improve outcomes for patients facing hard‑to‑treat cancer, enabling her to build a new international team to tackle one of the most urgent challenges in oncology: why treatments fail and how new therapies can improve outcomes for patients.

The Hughes Hall By-Fellow, a Research Associate with the University’s Department of Pathology for several years, and has now been appointed Assistant Professor at the University of Florence. She has been awarded funding for the new lab through the Italian Science Fund (FIS), Italy’s flagship research programme, as well as a competitive Start‑Up award from AIRC, the Italian Association for Cancer Research.

As she prepares to launch her lab, Dr Pucci will recruit a team including PhD students, research assistants and postdoctoral researchers, with hiring expected to begin from summer 2026.

Together, these awards provide substantial multi‑year investment to support independent, investigator‑led research. These funds enable ambitious, high‑impact scientific programmes, to allow researchers lead their own laboratories, including funding for research activity and the recruitment of research teams over a five‑year period.

Dr Pucci said: “This funding represents an important opportunity to investigate one of the biggest challenges in cancer treatment: why therapies stop working. Establishing my own laboratory will allow us to develop innovative approaches aimed at understanding and overcoming treatment resistance, with the ultimate goal of improving outcomes for patients with aggressive cancers.”

The new laboratory will focus on the role of non-coding RNAs (ncRNAs) in response to therapy in aggressive cancers, particularly high-risk neuroblastoma and aggressive variants of prostate cancer which are still incurable.

The research will combine cutting-edge approaches including CRISPR activation screens, Nanopore sequencing technologies, and the development of latest generation nanotherapies, with the aim of generating clinically relevant insights and new therapeutic strategies.

Dr Pucci will recruit a team including PhD students, research assistants and postdoctoral researchers, with hiring expected to begin from summer 2026.

She added: “Hughes Hall has been an incredibly supportive environment throughout my time in Cambridge. I am grateful for that support, and delighted to continue my connection with the College as a By-Fellow.

“As I start this new chapter, I hope the work we do will contribute to meaningful advances in cancer treatment and, importantly, make a significant difference for patients around the world fighting some of the most incurable forms of the disease.”

Dr Pucci is also preparing to publish new findings in the coming months, including studies on a newly identified oncogenic mutation in neuroblastoma and a promising gene‑targeted therapeutic approach.

Despite her move to Italy, Dr Pucci will remain a Fellow of Hughes Hall, maintaining strong links with the College community.

8.6.26